A
Description
Pharmaceutical company founded in 2016 by PhD students at the University of Rhode Island, headquartered in Rumford, RI. Develops new therapies for breast and ovarian cancers caused by BRCA1/BRCA2 mutations, focused on PARP inhibitors.